Philly Cancer Trial Gives Patient "Miracle" Results

Demetria Mears once felt so exhausted from her rare blood cancer that she couldn't bathe herself or feed her four children. Now, after joining a clinical trial in Philadelphia, she calls herself a "miracle child."

Mears has been battling myelofibrosis for more than a decade. The rare blood cancer causes the overproduction of blood cells and brings debilitating symptoms that left her unable to care for her family.

A doctor once told her she had three years to live. When chemotherapy failed to help, Mears found hope at Temple Health's Fox Chase Cancer Center.

The phase one trial combines two medications already approved by the FDA for other cancers with the standard treatment for myelofibrosis. Dr. Peter Abdelmessieh, a specialist at Temple Fox Chase, explains the goal is to reduce symptoms by at least 50%.

The approach targets the disease's root problem while helping patients manage their daily lives. Patients track their progress by rating how they feel, giving doctors clear feedback on what's working.

Why This Inspires

This trial shows how creative thinking can unlock new possibilities from existing tools. Rather than waiting years for entirely new medications, researchers are finding powerful combinations that can help people today.

For patients with rare diseases, these innovative approaches open doors when traditional options run out. The trial represents hope for families facing conditions with limited treatment choices.

Mears now has energy to care for her children again. She's grateful to feel like herself after years of exhaustion and worry.

While the experimental therapy isn't a cure, it's giving Mears something priceless: her life back. "At one point I thought I had no chance," she said. "I'm a living witness that it helps."